Other
2029
Amgen 2029 decreased by 17.9% to $2.30B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 17.9%, from $2.80B to $2.30B. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionOther
CategoryProfitability
SignalLower is better
VolatilityStable
First reportedQ1 2016
Last reportedQ1 2026
How to read this metric
Consistent projections allow for better predictability of future earnings and non-cash charges.
Detailed definition
This represents the projected amortization expense for finite-lived intangible assets for the year 2029. It is a forward...
Peer comparison
Standard disclosure for banks with significant historical acquisition activity.
Metric ID:
other_finite_lived_intangible_assets_amortization_expens_a9462eHistorical Data
15 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.40B | $2.40B | $2.40B | $2.40B | $2.20B | $2.20B | $2.10B | $2.10B | $3.90B | $3.90B | $3.90B | $2.80B | $2.90B | $2.80B | $2.30B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -8.3% | +0.0% | -4.5% | +0.0% | +85.7% | +0.0% | +0.0% | -28.2% | +3.6% | -3.4% | -17.9% |
| YoY Change | — | — | — | +0.0% | -8.3% | -8.3% | -12.5% | -4.5% | +77.3% | +85.7% | +85.7% | -28.2% | -25.6% | -28.2% | -17.9% |
Range$2.10B – $3.90B
CAGR-1.2%
Avg YoY Growth+9.6%
Median YoY Growth-8.3%
Current Streak2 quarters decline
2029 at Other Companies
Frequently Asked Questions
- What is Amgen's 2029?
- Amgen (AMGN) reported 2029 of $2.30B in Q1 2026.
- How has Amgen's 2029 changed year-over-year?
- Amgen's 2029 decreased by 17.9% year-over-year, from $2.80B to $2.30B.
- What does 2029 mean?
- The expected non-cash expense for acquired intangible assets in the year 2029.